CleanCap Technology: Leading the way in mRNA

Last updated: 28th April, 2020

CleanCap technology is a proprietary, co-transcriptional 5’ capping solution that generates a natural Cap 1 structure. Proper mRNA capping is critical to the production of the most biologically active and least immunogenic mRNA. TriLink scientists developed CleanCap, the next generation of capping technology, as a solution to the low capping efficiencies (mCAP/ARCA) or high enzyme costs that are associated with traditional capping methods.

CleanCap is efficient, elicits high yields of capped mRNA, and provides the highest quality mRNA 5’ cap structure available today. CleanCap is available in a variety of structures with specific initiation sequences. The newest analog to the CleanCap portfolio is CleanCap AU, optimized for self-amplifying mRNA vaccine development. Our robust suite of CleanCap capping strategies is available for endless application possibilities.

 

 

 

 

 

 

 

 

 

 


d


CleanCap is available as:

GMP Custom mRNA Manufacturing
Custom mRNA Manufacturing
Capping Reagent — Discovery and GMPLink™ grades
Stocked mRNA with CleanCap AG


CleanCap demonstrates superior performance versus legacy co-transcriptional capping methods

The unique combination of expertise in synthetic organic chemistry and pioneering knowledge in mRNA at TriLink enabled us to invent a chemical solution for a biological problem.

  • High capping efficiencies (94%+) resulting in more active mRNA
  • Yields a natural Cap 1 Product
    • Cap 1 reduces activation of Pattern Recognition Receptors
    • Dramatically increased activity in vivo in liver relative to Cap 0
  • “One pot” co-transcriptional reaction to produce a Cap 1 structure vs multiple purifications steps required for enzymatic Cap 1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


CleanCap gives superior activity in vivo by mimicking a natural cap

CleanCap results in a natural Cap 1 structure that reduces stimulation of the innate immune system of the host, resulting in unparalleled efficiency in vivo. Legacy co-transcriptional capping methods yield a Cap 0, an immunogenic cap structure that is poorly expressed in vivo.

The results speak for themselves: CleanCap, the next generation of cap analogs, provides the most active and least toxic mRNA for your in vivo applications.


Find out more about TriLink

Download Brochure >

Request a quote for CleanCap

Contact Us Now >



Request a Quote

Request Quote

Go BackGo Back
Top